Department of Urinary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
State Key Laboratory of Oncology in South China, Guangzhou, 510060, P. R. China.
BMC Cancer. 2024 Oct 8;24(1):1240. doi: 10.1186/s12885-024-13010-1.
Our study tried to evaluate the prognostic utility of preoperative serum cyfra21-1 in patients with penile squamous cell carcinoma (PSCC).
This retrospective study analyzed data from 94 patients who underwent either partial or radical penectomy accompanied by bilateral inguinal or pelvic lymphadenectomy at our institution from 2010 to 2018. The median duration of follow-up was 66.5 months. Serum cyfra21-1 concentrations were quantified through enzyme-linked immunosorbent assay, with patients classified into two groups based on cyfra21-1 levels (≤ 3.30 ng/ml and > 3.30 ng/ml). The impact of cyfra21-1 levels on clinical outcomes was evaluated.
Among the 94 patients, 68 (72.3%) had normal cyfra21-1 levels, while 26 (27.6%) exhibited elevated cyfra21-1 levels. During the follow-up period, 38 patients (40.4%) experienced relapse, and 35 patients (37.2%) died from PSCC. A significantly higher occurrence of advanced pathological grades was observed in the elevated cyfra21-1 group compared to the normal group (P = 0.029). Patients with elevated cyfra21-1 levels had significantly worse disease-free survival (DFS) and disease-specific survival (DSS) than those with normal levels (P < 0.001 and P < 0.001, respectively). In multivariate analysis, cyfra21-1 (HR: 3.938, 95% CI: 1.927-8.049, P < 0.001), lymph node involvement (HR: 8.277, 95% CI: 2.261-30.298, P = 0.001), pathological grade (HR: 2.789, 95% CI: 1.110-7.010, P = 0.029), and ECOG (Eastern Cooperative Oncology Group) performance status (HR: 1.751, 95% CI: 1.028-2.983, P = 0.039) were independent predictors of worse DFS. Similarly, CYFRA 21 - 1 (HR: 3.000, 95% CI: 1.462-6.156, P = 0.003), lymph node involvement (HR: 9.174, 95% CI: 2.010-41.862, P = 0.003), and ECOG performance status (HR: 1.856, 95% CI: 1.053-3.270, P = 0.032) were independent predictors of worse DSS.
High preoperative serum cyfra21-1 levels correlate with greater tumor aggressiveness and represent a novel, effective, and convenient prognostic biomarker for PSCC.
本研究旨在评估术前血清细胞角蛋白 21-1(cyfra21-1)在阴茎鳞癌(PSCC)患者中的预后价值。
本回顾性研究分析了 2010 年至 2018 年期间在我院接受部分或根治性阴茎切除术伴双侧腹股沟或盆腔淋巴结切除术的 94 例患者的数据。中位随访时间为 66.5 个月。通过酶联免疫吸附试验定量测定血清 cyfra21-1 浓度,根据 cyfra21-1 水平将患者分为两组(≤3.30ng/ml 和>3.30ng/ml)。评估 cyfra21-1 水平对临床结局的影响。
94 例患者中,68 例(72.3%)cyfra21-1 水平正常,26 例(27.6%)cyfra21-1 水平升高。在随访期间,38 例(40.4%)患者复发,35 例(37.2%)患者死于 PSCC。与正常组相比,cyfra21-1 升高组的高级别病理分级发生率明显更高(P=0.029)。cyfra21-1 水平升高组的无病生存率(DFS)和疾病特异性生存率(DSS)明显低于正常组(P<0.001 和 P<0.001)。多因素分析显示,cyfra21-1(HR:3.938,95%CI:1.927-8.049,P<0.001)、淋巴结受累(HR:8.277,95%CI:2.261-30.298,P=0.001)、病理分级(HR:2.789,95%CI:1.110-7.010,P=0.029)和 ECOG(东部肿瘤协作组)表现状态(HR:1.751,95%CI:1.028-2.983,P=0.039)是 DFS 较差的独立预测因素。同样,CYFRA 21-1(HR:3.000,95%CI:1.462-6.156,P=0.003)、淋巴结受累(HR:9.174,95%CI:2.010-41.862,P=0.003)和 ECOG 表现状态(HR:1.856,95%CI:1.053-3.270,P=0.032)是 DSS 较差的独立预测因素。
术前血清 cyfra21-1 水平升高与肿瘤侵袭性增加相关,是 PSCC 一种新的、有效且方便的预后生物标志物。